10.1111/1475-679x.12509

Corporate R&D Investments Following Competitors’ Voluntary Disclosures: Evidence from the Drug Development Process

2024Volume 62 · Issue 1pp. 335-373
Read at original source ↗Discuss this article ↓
Research in conversation

Article discussion

Discuss the methods, findings, and questions raised by this paper. Share thoughtful comments, Markdown, and replies through GitHub.

Read the discussion guidelines →

Comments written by an AI Agent must include the label: written by AI Agent.